News

Inform Genomics announces appointment of Megan Diaz Ellinghaus as part time outside general counsel

Jun 10
Responsible as corporate secretary and independent adviser for best corporate practice and joins company’s select group of officers Houston TX, June 10th, 2017: Inform Genomics, Inc., a privately held company that utilizes a proprietary analytic platform to develop genomic-based, precision medicine products, announces the appointment of Megan Diaz Ellinghaus as part time General Counsel and Corporate Secretary. Megan Diaz Ellinghaus,

Inform Genomics announces appointment of William M. Shields to Board of Directors

Oct 27
Treasurer becomes 3rd independent director to join company’s Board Boston, MA–October 27, 2016–Inform Genomics, Inc., a privately held company that utilizes a proprietary analytic platform to develop genomic-based, precision medicine products, announces the appointment of William (Bill) M. Shields, company Treasurer to Board of Directors. He has been named to Covington’s List of Top One Hundred Accounting Professionals and currently

Inform Genomics announces filing of patent application in Taiwan

Sep 30
“systems and methods for predicting treatment-regimen-related outcomes” Boston MA, September 30th, 2016: Inform Genomics, Inc., a privately held company that utilizes a proprietary analytic platform to develop genomic-based, precision medicine products, announces preliminary patent filing in Taiwan by the Company’s outside intellectual property counsel, Jones Day. “We are excited to have Jones Day extend our potential intellectual property portfolio with

Inform Genomics announces international filing of patents via patent cooperation treaty

Sep 29
“systems and methods for predicting treatment-regimen-related outcomes” Boston MA –September 29th, 2016–Inform Genomics, Inc., a privately held company that utilizes a proprietary analytic platform to develop genomic-based, precision medicine products, announces international filing through the central patent cooperation treaty by the Company’s outside intellectual property counsel, Jones Day. “We are very happy to have Jones Day extend our potential intellectual property

Inform Genomics Presents Biologic Validity for OnPART™ Predictive Networks Identifying Potential Genomic Targets for Drug Discovery

Jun 03
Poster selected for discussion during patient and survivor care session at 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago Boston, MA – June 3, 2013 – Inform Genomics, Inc., a private company focused on developing novel platforms of genomic-based personalized medicine products for cancer supportive care, presented the biologic validity of its lead platform product, OnPART™, on